More black men to benefit from prostate cancer screening trial

A significant expansion of a UK prostate cancer screening trial will now invite tens of thousands more Black men aged 45 to 74 for checks. This initiative aims to improve testing accuracy and address disparities in the disease's impact on this demographic.

“

Tens of thousands more black men aged 45-74 are to be invited for prostate cancer checks as part of an ongoing trial in the UK to find better ways of testing for the disease.

The trial, funded by an £18 million government investment, is exploring methods beyond the standard Prostate-Specific Antigen (PSA) blood test. Health officials acknowledge that while PSA tests can save lives, they also carry risks of leading to treatments for slow-growing tumors that may never become life-threatening. These treatments can result in side effects like incontinence and erectile dysfunction.

“

The committee says the harms of using a blood test, called PSA, for screening outweigh the benefits in the majority of cases, except for "a few thousand" men who have a dangerous genetic variant and a family history of cancer.

Prostate cancer is the most common cancer among men in the UK, with one in eight men diagnosed in their lifetime. This risk doubles to one in four for Black men. The current trial is assessing the effectiveness of additional tests, such as genetic screening and faster MRI scans, alongside PSA tests.

“

Prostate cancer is the most common cancer in men in the UK, with 64,000 men diagnosed and 12,000 dying each year. One in eight men will get prostate cancer in their lifetime and for black men, that risk doubles to one in four.

Health Secretary James Murray hailed the expansion as a "major step forward" in tackling prostate cancer, emphasizing the focus on high-risk groups, improving treatments, and closing evidence gaps to save lives. Prostate Cancer UK welcomed the decision, anticipating it will help the charity reach more Black men with reliable information.

“

This is a major step forward in how we tackle prostate cancer - focusing on those most at risk, improving the treatments available, and backing the research we need to close the evidence gaps and save lives.